Overview: PIVKA-II (DCP PIVKA-II) TestIntroduction: The PIVKA-II Test measures des-gamma carboxy prothrombin (DCP) as a marker for liver cancer, causing jaundice or abdominal pain. Following 2023 AASLD guidelines, it uses an immunoassay for high sensitivity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected hepatocellular carcinoma.
Other Names: DCP Assay, PIVKA-II Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: PIVKA-II testing began in the 1980s with liver cancer research. Immunoassays emerged in the 1990s, and by the 2000s, high-sensitivity assays improved accuracy.
Purpose: Diagnoses liver cancer, guides treatment, and monitors DCP levels in patients with jaundice or abdominal pain.
Test Parameters: 1. Des-Gamma Carboxy Prothrombin
Pretest Condition: Fasting for 10-12 hours required. Collect serum at any time. Report symptoms like jaundice or abdominal pain, and list liver disease history.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, abdominal pain, or history of liver disease (e.g., hepatitis). Include current medications, especially antineoplastics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses an immunoassay to measure PIVKA-II levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Vitamin K deficiency or liver disease can elevate levels. Hemolysis may degrade samples.
Clinical Significance: Elevated PIVKA-II levels suggest liver cancer, prompting imaging or biopsy. Normal levels may require further testing.
Specialist Consultation: Consult an oncologist or hepatologist for result interpretation.
Additional Supporting Tests: AFP test, liver ultrasound, or CT scan to confirm liver cancer.
Test Limitations: Non-specific elevations may occur in non-cancer liver conditions. Results require clinical correlation.
References: AASLD Liver Cancer Guidelines, 2023; Hepatology, Marrero JA, 2022.
